A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer-Reference-Cited by-同舟云学术

A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer

Published:2017-11-30 Issue:67 Volume:8 Page:111346-111355
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Yoshida Kensaku¹,Iwashita Takuji¹,Uemura Shinya¹,Maruta Akinori¹,Okuno Mitsuru¹,Ando Nobuhiro²,Iwata Keisuke²,Kawaguchi Junji³,Mukai Tsuyoshi³,Shimizu Masahito¹

Affiliation:

1. First Department of Internal Medicine, Gifu University Hospital, Gifu, Japan

2. Department of Gastroenterology, Gifu Prefectural General Medical Center, Gifu, Japan

3. Department of Gastroenterology, Gifu Municipal Hospital, Gifu, Japan

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Prophylactic Efficacy of Eflapegrastim and Pegteograstim for Chemotherapy-induced Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX/mFOLFIRINOX;Journal of Korean Society of Health-System Pharmacists;2024-08-31

2. Evaluation of the Treatment Duration of Japanese Patients With Pancreatic Cancer in a Real-World Setting Using a Large Hospital Claims Database;Pancreas;2024-05-16

3. Modeling health outcomes associated with BRCA testing and treatment strategies for patients with metastatic pancreatic cancer;Pancreatology;2024-03

4. Efficacy and safety of 5HT3RA, DEX, and NK1RA for the prevention of FOLFIRINOX-induced nausea and vomiting in patients with pancreatic cancer: a retrospective cohort study;Supportive Care in Cancer;2023-10-26

5. Incidence and non-genetic risk factors of irinotecan-induced severe neutropenia in Chinese adult inpatients;Medicine;2023-03-03